Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 2 of the 7 sources its claims cite were checked for support.
Abstract
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in September 2020 and is rapidly spreading toward fixation. Using a variety of statistical and dynamic modeling approaches, we estimate that this variant has a 43 to 90% (range of 95% credible intervals, 38 to 130%) higher reproduction number than preexisting variants. A fitted two-strain dynamic transmission model shows that VOC 202012/01 will lead to large resurgences of COVID-19 cases. Without stringent control measures, including limited closure of educational institutions and a greatly accelerated vaccine rollout, COVID-19 hospitalizations and deaths across England in the first 6 months of 2021 were projected to exceed those in 2020. VOC 202012/01 has spread globally and exhibits a similar transmission increase (59 to 74%) in Denmark, Switzerland, and the United States.
Overview
CoChat Summary
TL;DR
Using sequencing, mobility/contact data, and dynamic transmission models, the paper finds that SARS-CoV-2 lineage B.1.1.7 (VOC 202012/01) spread substantially faster than prior lineages in England. The authors estimate it is 43 to 90% more transmissible, with no clear evidence of increased disease severity, but warn that faster spread would increase cases, hospitalizations, and the need for stronger control measures and faster vaccination.
Key findings
- In UK sequencing data, VOC 202012/01 had the highest relative population growth rate among 307 other lineages in the first 31 days after initial phylogenetic observation, and it continued to expand.
- A multinomial spline model estimated an increased growth rate of +0.104 day–1 relative to B.1.177, corresponding to a 77% increase in reproduction number R (95% CI, 73 to 81%) assuming a 5.5-day generation interval.
- Alternative analyses estimated R for VOC 202012/01 to be 43% higher (95% CI, 38 to 48%) from case-based regression, and 55% higher in Denmark, 74% higher in Switzerland, and 59% higher in the United States.
- The transmission model found no clear increase or decrease in severity, with odds ratios of 0.92 for hospitalization, 0.90 for critical illness, and 0.90 for death, but estimated transmissibility was 65% higher in the three most affected NHS regions and 82% higher across all seven regions.
Methods
- The study combined publicly available sequencing data from COG-UK, Pillar 2 testing data for S gene target failure, mobility data from Google Community Mobility, and social contact data from the CoMix survey, plus analogous sequence/RT-PCR data from Denmark, Switzerland, and the US.
- The authors used multinomial and binomial generalized linear mixed models, negative binomial state-space models, and an age- and region-structured deterministic compartmental transmission model fitted to multiple regional data streams, including deaths, hospital admissions, bed occupancy, PCR prevalence, seroprevalence, and VOC frequency.
- They compared five mechanistic hypotheses for the rapid spread, assessed model fit with deviance information criteria and short-term prediction, and ran scenario projections under varying NPIs and vaccination rollout rates.
Limitations
- The paper states that only a small number of intervention and vaccination scenarios were considered, and these should not be viewed as the only policy options.
- It states that the transmission model does not explicitly capture nursing home or hospital transmission, and regions were fit separately rather than jointly modeling between-region transmission.
- It notes uncertainty in model choice and parameter assumptions, including school-closure assumptions and NPI efficacy; these are limitations stated in the paper.
- Evident from the text: the severity analysis is based on early population-level data up to 24 December 2020, so delays from infection to hospitalization or death could obscure severity effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 2 Measuring the growth rate of VOC 202012/01. (A) Average relativized growth rate (i.e., a measure of variant fitness relative to other variants present during the 31 days after initial phylogenetic observation of a given variant) for all lineages in the COG-UK dataset, highlighting many lineages that have risen to prominence including B.1.177, the lineage with the highest relative abundance during the initial phylogenetic observation of VOC 202012/01. The shaded regions show conservative 95% rejection intervals; VOC 202012/01 is the first strain to exceed this threshold of faster relativized growth. Although many lineages exhibit above-average rates of growth, VOC 202012/01 has had the highest average relativized growth of any lineage in the history of COG-UK surveillance of SARS-COV-2. (B) Plotting all lineages’ relativized growth rates [ρ(t)] as a function of lineage age with conservative 95% rejection intervals highlights the significantly faster growth of VOC 202012/01 relative to other lineages at comparable times since their initial observation. Later declines in VOC and B.1.177 correspond to highly uncertain estimates of growth rates for data that are yet to be backfilled, so these declines in ρ(t) are sensitive to the processing of future sequences from recent dates (fig. S1). (C) Muller plots of the relative abundances of the major SARS-CoV-2 variants in the UK, based on a multinomial spline fit to COG-UK sequence data (Table 1 and table S1, separate-slopes multinomial spline model). A model extrapolation until 1 March 2021 is shown (shaded area). Minority variants are 440 circulating SARS-CoV-2 variants of low abundance. Specific colors represent the same lineages in (A) to (C). (D) Mean reproduction number over 7-day periods in 149 upper-tier local authorities of England (colored by the NHS England region they are within) plotted against the weekly proportion of Pillar 2 community SARS-CoV-2 tests with S gene target failure shows the spread of VOC 202012/01, a corresponding increase in the reproduction number in each local authority, and the eventual impact of targeted government restrictions from 20 December 2020. Testing data are shown for the week after the reproduction number estimates to account for delays from infection to test.](https://figures.cochat.ai/paper-figures/6a959b32b94b41a4aab77f4b47b25a40/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-2.jpg)
![Fig. 3 Comparison of possible biological mechanisms underlying the rapid spread of VOC 202012/01. Each row shows a different assumed mechanism. (A) Relative frequency of VOC 202012/01 (black line and ribbon respectively denote observed S gene target failure frequency with 95% binomial credible interval; purple line and ribbon respectively denote mean and 95% credible interval from model fit). (B) Posterior estimates (mean and 95% credible intervals) for relative odds of hospitalization (severe illness), relative odds of ICU admission (critical illness), relative odds of death (fatal illness), growth rate as a multiplicative factor per week [i.e., exp(7·∆r)], and the parameter that defines the hypothesized mechanism; all parameters are relative to those estimated for preexisting variants. (C to E) Illustrative model fits for the South East NHS England region: (C) fitted two-strain increased transmissibility model with VOC 202012/01 included; (D) fitted two-strain increased transmissibility model with VOC 202012/01 removed; (E) fitted single-strain model without emergence of VOC 202012/01. Black lines denote observed data; error bars denote the date range and 95% credible intervals for observed PCR prevalence and seroprevalence; colored lines and ribbons denote median and 95% credible intervals from model fit.](https://figures.cochat.ai/paper-figures/806d848e45ca40c19e0cc853e2b24dfc/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-3.jpg)

Verification
Claims the paper makes
2 Valid · 0 Not valid · 4 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we did not find substantial differences in social interactions between regions of high and low VOC 202012/01 prevalence, as measured by Google mobility (11) and social contact survey data (12) from September to December 2020 (Fig. 1, E and F).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
What the sources say
- Not matchedcites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Methods (Survey methodology) identify this as the CoMix social-contact survey, supporting the citation’s identification of the survey. But the Results (Participant characteristics) say the data reported here were collected on 24–27 March 2020; this paper does not establish that its reported data cover September–December 2020. The comparison between regions is presented as the citing authors’ own finding, not a finding attributed to this source. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This yielded an estimated increase in R for VOC 202012/01 of 43% (95% CI, 38 to 48%), increasing to a 57% (95% CI, 52 to 62%) increase if the spline was not included (Table 1, models 4a and 4b).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants.”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Discussion Combining multiple behavioral and epidemiological data sources with statistical and dynamic modeling, we estimated that the SARS-CoV-2 variant VOC 202012/01 has a 43 to 90% (range of 95% CrIs, 38 to 130%) higher reproduction number than preexisting variants of SARS-CoV-2 in England, assuming no changes to the generation interval. On the basis of early population-level data, we were unable to identify whether the new variant is associated with higher disease severity. Theoretical considerations suggest that, in some cases, natural selection may favor reduced severity of disease in pathogens (23). For this to be true, however, the pathogen’s infectious period must be truncated by disabling symptoms or death often enough that a less-virulent mutant generates more secondary infections despite potentially being less transmissible per contact, to the extent that decreased virulence and decreased transmissibility are consequences of the same mutation (e.g., one that decreases viral load). It is far from clear that this condition holds for SARS-CoV-2, given substantial transmission before the onset of severe symptoms. Regardless, without strengthened controls, there is a clear risk that future epidemic waves may be larger—and hence associated with greater burden—than previous waves. The UK government initiated a third national lockdown on 5 January 2021 in response to the rapid spread of VOC 202012/01, including school closures. Educational settings are among the largest institutions linked to SARS-CoV-2 clusters that remained open during the November 2020 lockdown (24), which means that the enacted school and university closures may have substantially assisted in reducing the burden of COVID-19 in early 2021. The increase in transmission associated with VOC 202012/01 has crucial implications for vaccination. First, it means that prompt and efficient vaccine delivery and distribution are even more important to reduce the impact of the pandemic in the near future. Increased transmission resulting from VOC 202012/01 will raise the herd immunity threshold, so that the potential burden of SARS-CoV-2 is larger and higher vaccine coverage will be required to achieve herd immunity. It is therefore extremely concerning that VOC 202012/01 has spread to at least 114 countries globally (2). Although VOC 202012/01 was first identified in England, a rapidly spreading variant has also been detected in South Africa (25, 26), where there was a marked increase in transmission in late 2020. Another variant exhibiting immune escape has emerged in Brazil (27, 28). Thus, vaccination timelines will also be a crucial determinant of future burden in other countries where similar new variants are present. Second, there is a need to assess how VOC 202012/01 and other emerging lineages affect the efficacy of vaccines (29, 30). Vaccine developers may need to consider developing formulations with variant sequences, and they may want to initiate post-licensure studies to detect differences in efficacy between the preexisting and new variants. Licensing authorities may need to clarify abbreviated pathways to marketing for vaccines that involve altering strain formulation without any other changes to their composition. There are limitations to our analysis. We have considered a small number of intervention and vaccination scenarios, which should not be regarded as the only available options for policy-makers. Our transmission model does not explicitly capture nursing home or hospital transmission of SARS-CoV-2, and we fit the model to each region of England separately rather than pooling information across regions and explicitly modeling transmission between regions. There are also uncertainties in the choice of model used to generate these predictions, and the exact choice will yield differences in the measures needed to control the epidemic. We note that even without increased susceptibility of children to VOC 202012/01, the more efficient spread of the variant implies that the difficult societal decision of closing schools will be a key public health question for multiple countries in the months ahead. We only assess relative support in the data for the mechanistic hypotheses proposed, but there may be other plausible mechanisms driving the resurgence of cases that we did not consider, and we have not identified the specific combination of mechanisms driving the increased transmission of VOC 202012/01. We identify increased transmissibility as the most parsimonious mechanistic explanation for the higher growth rate of VOC 202012/01, but a longer infectious period also fits the data well (table S4) and is supported by longitudinal testing data (17). Our conclusions about school closures were based on the assumption that children had reduced susceptibility and infectiousness relative to adults (19), but the precise values of these parameters and the impact of school closures remain the subject of scientific debate (31). We based our assumptions about the efficacy of NPIs on the measured impact on mobility of previous national lockdowns in England, but the impact of policy options cannot be predicted with certainty. Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants. Our modeling analysis suggests that this difference could be explained by an overall higher infectiousness of VOC 202012/01, but not by a shorter generation time or immune escape alone. Further experimental work will provide insight into the biological mechanisms for our observations, but given our projections of a rapid rise in incidence from VOC 202012/01—and the detection of other novel and highly transmissible variants (25–28)—there is an urgent need to consider what new approaches may be required to sufficiently reduce the ongoing transmission of SARS-CoV-2.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the relative population growth rate of VOC 202012/01 in the first 31 days after its initial phylogenetic observation was higher than that of all 307 other lineages with enough observations to obtain reliable growth-rate estimates (Fig. 2A and fig. S1).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
plainn = 150,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of COVID-19 cases attributable to VOC 202012/01 increased rapidly in all regions of England, following an initial expansion in the southeast (Fig. 1A)”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 43 claims and every source verdict.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“B.1.1.7 to be between 43% and 82%3 more transmissible than preexisting variants in the United Kingdom.”
From New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, viral variants of concern have emerged in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several emerging viral variants of concern have been identified that have mutations in the spike protein, including the B.1.1.7 variant (originating from the UK and which has eight spike mutations92), the B.1.351 variant (originating from South Africa) and the P.1 variant (originating from Brazil and which also contains multiple mutations in the spike protein and is spreading widely)57,93.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiological studies suggest that it was approximately 50% more transmissible than previously circulating UK variants 191,197,198 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“it has been previously reported that B.1.1.7 is associated with lower Ct values, corresponding to higher VLs 3”
From Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals (2021) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
Markov Processes: Characterization and Convergence
Ethier, S. N., & Kurtz, T. G. (1986) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316658 · Cited by 3,634
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
Advanced Bayesian Multilevel Modeling with the R Package brms
Bürkner, P.-C. (2018) · The R Journal · doi:10.32614/rj-2018-017 · Cited by 3,015 · cited 9×
“168) 67 (53-83) 120 (92-152) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE North West VOC vs.”
BackgroundMethodInfluentialSocial Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900 · cited 10×
“105) 43 (40-46) 72 (67-78) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London VOC vs.”
BackgroundInfluentialSelf-citationProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 8×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundResultInfluentialEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Self-citationA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 10×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundInfluential
Cited by
Items 501–600 of 2,327
Brandherm, L., Kobaš, A. M., Klöhn, M., Brüggemann, Y., Pfaender, S., Rassow, J., & Kreimendahl, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179233 · Cited by 43
Anderson, R. M., Vegvari, C., Hollingsworth, T. D., Pi, L., Maddren, R., Ng, C. W., & Baggaley, R. F. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0008 · Cited by 45
Quantifying contact patterns in response to COVID-19 public health measures in Canada
Brankston, G., Merkley, E., Fisman, D. N., Tuite, A. R., Poljak, Z., Loewen, P. J., & Greer, A. L. (2021) · BMC Public Health · doi:10.1186/s12889-021-12080-1 · Cited by 39
Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M., Rehrauer, W., Zheng, N.-Y., et al. (2021) · mBio · doi:10.1128/mbio.02975-21 · Cited by 41
Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy
Giallonardo, F. D., Puglia, I., Curini, V., Cammà, C., Mangone, I., Calistri, P., Cobbin, J. C. A., Holmes, E. C., & Lorusso, A. (2021) · Viruses · doi:10.3390/v13050794 · Cited by 39
“7 is associated with both a higher production number and a greater hazard of death [5].”
BackgroundMonitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages
Jewell, B. L. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00073-6 · Cited by 36
Increased Transmissibility of the SARS-CoV-2 Alpha Variant in a Japanese Population
Tanaka, H., Hirayama, A., Nagai, H., Shirai, C., Takahashi, Y., Shinomiya, H., Taniguchi, C., & Ogata, T. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18157752 · Cited by 39
The variants of SARS‐CoV‐2 and the challenges of vaccines
Han, X., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27513 · Cited by 46
The challenges of data in future pandemics
Shadbolt, N., Brett, A., Chen, M., Marion, G., McKendrick, I. J., Panovska‐Griffiths, J., Pellis, L., Reeve, R. E., & Swallow, B. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100612 · Cited by 44
“…et al., 2020; Panovska-Griffiths et al., 2020), evaluating emerging questions such as the transmissibility and severity of the B.1.1.7 variant (Davies et al., 2021; Challen et al., 2021), or evaluating the roadmap of reopening society as vaccination roll out continues (Whittles et al., 2021;…”
BackgroundInfluentialNapolitano, F., Xu, X., & Gao, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab456 · Cited by 42
A COVID-19 vaccination model for Aotearoa New Zealand
Steyn, N., Plank, M. J., Binny, R. N., Hendy, S. C., Lustig, A. G., & Ridings, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-06707-5 · Cited by 35
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomić, A., Skelly, D., Ogbe, A., O’Connor, D., Pace, M. J., Adland, E., Alexander, F., Ali, M., Allott, K., Ansari, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28898-1 · Cited by 37
Self-citationvon Wintersdorff, C. J. H., Dingemans, J., van Alphen, L. B., Wolffs, P. F. G., van der Veer, B. M. J. W., Hoebe, C. J. P. A., & Savelkoul, P. H. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-18279-5 · Cited by 50
Dicken, S. J., Murray, M. J., Thorne, L., Reuschl, A., Forrest, C., Ganeshalingham, M., Muir, L., Kalemera, M. D., Palor, M., McCoy, L. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.22.436468 · Cited by 33
“7 exhibits increased transmissibility and pathogenesis (5, 12) compared to its direct predecessor (i.”
BackgroundMartinez, D. R., Schaefer, A., Gobeil, S., Li, D., la Cruz, G. D., Parks, R., Lu, X., Barr, M., Manne, K., Mansouri, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.27.441655 · Cited by 37
COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United StatesPreprint
Moghadas, S. M., Sah, P., Fitzpatrick, M. C., Shoukat, A., Pandey, A., VILCHES, T. N., Singer, B. H., Schneider, E. C., & Galvani, A. P. (2021) · medRxiv · doi:10.1101/2021.07.07.21260156 · Cited by 36
Spinello, A., Saltalamacchia, A., Borišek, J., & Magistrato, A. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c01415 · Cited by 38
Distinct lipid metabolic dysregulation in asymptomatic COVID-19
Hao, Y., Zhang, Z., Feng, G., Chen, M., Wan, Q., Lin, J., Wu, L., Nie, W., & Chen, S. (2021) · iScience · doi:10.1016/j.isci.2021.102974 · Cited by 37
“A recent study estimated the B.1.1.7 SARS-CoV-2 variant is 43%–90% more transmissible than preexisting variants and predicted a higher number of coronavirus deaths across England in 2021 than those in 2020 (Davies et al., 2021).”
InfluentialSARS-CoV-2 neutralising antibodies in dogs and cats in the United Kingdom
Smith, S. L., Anderson, E. R., Cansado-Utrilla, C., Prince, T., Farrell, S., Brant, B., Smyth, S., Noble, P. M., Pinchbeck, G. L., Marshall, N., et al. (2021) · Current Research in Virological Science · doi:10.1016/j.crviro.2021.100011 · Cited by 37
“7) has altered transmissibility to cats and dogs as it does in humans (Davies et al., 2021).”
SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications
Toropov, N. A., Osborne, E. L., Joshi, L. T., Davidson, J., Morgan, C., Page, J. W., Pepperell, J., & Vollmer, F. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00612 · Cited by 36
Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R. A., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021) · Journal of Virology · doi:10.1128/jvi.01110-21 · Cited by 37
“7 lineage variants are highly contagious (27, 28) and have become dominant throughout the US (23).”
BackgroundMamedov, T., Yuksel, D., Ilgın, M., Gürbüzaslan, İ., Gulec, B., MAMMADOVA, G., Özdarendeli, A., Yetişkin, H., Kaplan, B., Pavel, S. T. I., et al. (2021) · Vaccines · doi:10.3390/vaccines9111337 · Cited by 42
Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China
Liu, H., Zhang, J., Cai, J., Deng, X., Peng, C., Chen, X., Yang, J., Wu, Q., Chen, X., Chen, Z., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02243-1 · Cited by 37
Kim, Y., Gaudreault, N. N., Meekins, D. A., Perera, K. D., Bold, D., Trujillo, J. D., Morozov, I., McDowell, C. D., Chang, K., & Richt, J. A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01789-21 · Cited by 38
Zarkoob, H., Allué‐Guardia, A., Chen, Y., Garcia‐Vilanova, A., Jung, O., Coon, S. L., Song, M. J., Park, J., Oladunni, F. S., Miller, J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03753-7 · Cited by 38
Evolutionary remodelling of N‐terminal domain loops fine‐tunes SARS‐CoV‐2 spike
Cantoni, D. M., Murray, M. J., Kalemera, M. D., Dicken, S. J., Stejskal, L., Brown, G., Lytras, S., Coey, J. D., McKenna, J. P., Bridgett, S., et al. (2022) · EMBO Reports · doi:10.15252/embr.202154322 · Cited by 40
Investigating the evolutionary origins of the first three SARS-CoV-2 variants of concern
Ghafari, M., Liu, Q., Dhillon, A., Katzourakis, A., & Weissman, D. B. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.942555 · Cited by 38
Brunner, F. S., Brown, M. R., Bassano, I., Denise, H., Khalifa, M. S., Wade, M. J., van Aerle, R., Kevill, J. L., Jones, D. L., Farkas, K., et al. (2022) · Water Research · doi:10.1016/j.watres.2022.119306 · Cited by 35
“One million SARS-CoV-2 genomes were sequenced worldwide by April 2021, rising to over seven million by January 2022 on the GISAID database (Elbe and Buckland-Merrett, 2017).”
BackgroundAnti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel, E., Reix, N., et al. (2021) · doi:10.1101/2021.05.07.21256823 · Cited by 240
“8) Time from symptom onset to serum collection at: M1 (days), median (IQR; range) 31 (24-38; 6-58) 32 (24-38; 6-53) 29 (24-37; 13-58) 0.”
The Longer Students Were Out of School, the Less They Learned
Patrinos, H. A. (2023) · Journal of School Choice · doi:10.1080/15582159.2023.2210941 · Cited by 35
“…NW, Washington DC 20433, USA © 2023 Taylor & Francis shows that the health benefits of school closures seemed to have been lower than the cost of learning losses (Allen, 2022; Davies et al., 2020, 2021; Gandini et al., 2021; Lee & Raszka, 2020; Ludvigsson, 2020; Raffetti & Di Baldassarre, 2022).”
BackgroundDetecting Rapid Spread of SARS-CoV-2 Variants, France, January 26–February 16, 2021
Haïm‐Boukobza, S., Roquebert, B., Trombert‐Paolantoni, S., Lecorché, E., Verdurme, L., Foulongne, V., Selinger, C., Michalakis, Y., Sofonea, M. T., & Alizon, S. (2021) · Emerging infectious diseases · doi:10.3201/eid2705.210397 · Cited by 39
“39 *For categorical variables, reference values are the other kit (1) and the hospital setting.”
BackgroundThe potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant
Hodgson, D., Flasche, S., Jit, M., Kucharski, A. J., & CMMID COVID-19 Working Group (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.20.2100428 · Cited by 35
Self-citationRodríguez-Maldonado, A. P., Vázquez-Pérez, J. A., Cedro‐Tanda, A., Taboada, B., Boukadida, C., Wong-Arámbula, C. E., Núñez-García, T. E., Cruz-Ortiz, N., Barrera-Badillo, G., Hernández‐Rivas, L., et al. (2021) · Archives of Virology · doi:10.1007/s00705-021-05208-6 · Cited by 34
Impact of January 2021 curfew measures on SARS-CoV-2 B.1.1.7 circulation in France
Domenico, L. D., Sabbatini, C. E., Pullano, G., Lévy-Bruhl, D., & Colizza, V. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.15.2100272 · Cited by 42
“7 estimated for France on Flash1 and Flash2 survey data [4] in line with previous estimates [1,2] and assumed complete cross-immunity [1,2].”
InfluentialCaldwell, J. M., de Lara-Tuprio, E. P., Teng, T. R. Y., Estuar, M. R. J. E., Sarmiento, R. F., Abayawardana, M., Leong, R. N. F., Gray, R. T., Wood, J., Le, L., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100211 · Cited by 48
Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology
Caldwell, J. M., Le, X., McIntosh, L., Meehan, M. T., Ogunlade, S. T., Ragonnet, R. R., O’Neill, G. K., Trauer, J. M., & McBryde, E. S. (2021) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2021.07.002 · Cited by 40
“7) has been estimated to be 60% more transmissible than the wild-type SARS-CoV-2 strain [21], implying a HIT of 80%.”
Villa, A. M., Brunialti, E., Dellavedova, J., Meda, C., Rebecchi, M., Conti, M., Donnici, L., Francesco, R. D., Reggiani, A. M., Lionetti, V., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105982 · Cited by 40
VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Prates-Syed, W. A., Chaves, L. C. S., Crema, K. P., Vuitika, L., Lira, A. A. D. L., Côrtes, N., Kersten, V., Guimarães, F. E. G., Sadraeian, M., da Silva, F. L. B., et al. (2021) · Vaccines · doi:10.3390/vaccines9121409 · Cited by 39
“The VOCs that have attracted the most attention so far are the Alpha, Beta, Gamma, and Delta variants [108], which were initially identified in the UK [109], South Africa [112], Brazil [113], and India [114], respectively (Figure 4).”
Backgroundda Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 38
“The N501Y and A570D mutations, located in the region binding domain (RBD), have been related to increase of viral binding affinity to ACE2 host receptor, contributing to transmissibility (33, 57, 93).”
BackgroundInfluentialCharacterization and structural basis of a lethal mouse-adapted SARS-CoV-2Preprint
Sun, S., Gu, H., Cao, L., Chen, Q., Ye, Q., Yang, G., Li, R.-T., Fan, H., Deng, Y., Song, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.10.377333 · Cited by 35
SARS‐CoV ‐2 biology and variants: anticipation of viral evolution and what needs to be done
Luo, R., Delaunay, A., Timmis, K. N., & Danchin, A. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15487 · Cited by 40
“However, of the three major variants (Zhou et al., 2021) which have recently been identified, increased severity has been explicitly demonstrated in the B.1.1.7 variant (Davies et al., 2021).”
BackgroundInfluentialWang, M., Zhang, L., Li, Q., Wang, B., Liang, Z., Sun, Y., Nie, J., Wu, J., Su, X., Qu, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2008775 · Cited by 35
“These mutations can alter the transmissibility [15], disease severity [16] and antigenicity characteristics”
BackgroundBeesley, L. J., Moran, K. R., Wagh, K., Castro, L. A., Theiler, J. P., Yoon, H., Fischer, W., Hengartner, N., Korber, B., & Valle, S. Y. D. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104534 · Cited by 38
Vaquero, S. T., de Campos‐Mata, L., Ramada, J. M., Díaz, P., Navarro‐Barriuso, J., Ribas‐Llauradó, C., Melero, N. R., Carolis, C., Cerutti, A., Gimeno, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737083 · Cited by 39
Interventions to control nosocomial transmission of SARS-CoV-2: a modelling study
Pham, T. M., Tahir, H., van de Wijgert, J. H. H. M., der Roest, B. R. V., Ellerbroek, P. M., Bonten, M. J. M., Bootsma, M., & Kretzschmar, M. (2021) · BMC Medicine · doi:10.1186/s12916-021-02060-y · Cited by 41
“7, we assumed a 56% increase in transmissibility [25].”
BackgroundTostanoski, L. H., Yu, J., Mercado, N. B., McMahan, K., Jacob-Dolan, C., Martinot, A. J., Piedra-Mora, C., Anioke, T., Chang, A., Giffin, V. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj3789 · Cited by 31
Munster, V. J., Flagg, M., Singh, M., Yinda, C. K., Williamson, B. N., Feldmann, F., Pérez-Pérez, L., Schulz, J. E., Brumbaugh, B., Holbrook, M. G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj3627 · Cited by 36
Zhang, Y.-N., Paynter, J., Sou, C., Fourfouris, T., Wang, Y., Abraham, C., Ngo, T., Zhang, Y., He, L., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abj3107 · Cited by 35
Bayarri‐Olmos, R., Johnsen, L. B., Idorn, M., Reinert, L. S., Rosbjerg, A., Vang, S., Hansen, C. B., Helgstrand, C., Bjelke, J. R., Bak-Thomsen, T., et al. (2021) · eLife · doi:10.7554/elife.70002 · Cited by 35
Targeted vaccination and the speed of SARS-CoV-2 adaptation
Gandon, S., & Lion, S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110666119 · Cited by 33
“2 Discussion The speed of the spread of SARS-CoV-2 variants has baffled the scientific community [7, 8].”
BackgroundThe rise and spread of the SARS-CoV-2 AY.122 lineage in Russia
Klink, G. V., Safina, K. R., Nabieva, E., Shvyrev, N., Garushyants, S. K., Alekseeva, E. I., Komissarov, A. B., Danilenko, D., Pochtovyi, A. A., Divisenko, E. V., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac017 · Cited by 36
“2 variants are certainly characterized by changed fitness due to changes in transmissibility and/or immune avoidance [2], much of the geographical difference and dynamics of SARS-CoV-2 lineages is due to epidemiological factors”
Liu, Y., Pearson, C. A. B., Sandmann, F., Barnard, R. C., Kim, J., CMMID COVID-19 Working Group, Flasche, S., Jit, M., & Abbas, K. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100381 · Cited by 37
“16,18,25 There is additional uncertainty around these parameters that are not captured in our study.”
Self-citationZhang, G. F., Meng, W., Chen, L., Ding, L., Feng, J., Pérez, J., Ali, A., Sun, S., Liu, Z., Huang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28032 · Cited by 35
Mandatory COVID-19 vaccination for healthcare workers: A discussion paper
Maneze, D., Salamonson, Y., Grollman, M., Montayre, J., & Ramjan, L. M. (2022) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2022.104389 · Cited by 37
“Before the emergence of variants, on average, each infected person could transmit the infection to 2.2 people (Li et al., 2020), but amore recent study showed increased transmissibility of the infection by 43 % to 82 % (Davies et al., 2021).”
InfluentialSARS-CoV-2 variants: Impact on biological and clinical outcome
Mahilkar, S., Agrawal, S. R., Chaudhary, S., Parikh, S., Sonkar, S. C., Verma, D. K., Chitalia, V., Mehta, D., Koner, B. C., Vijay, N., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.995960 · Cited by 43
“Beta VOC The Beta VOC was reported to be more transmissible than the ancestral SARS-CoV-2 strain and successfully evaded Frontiers inMedicine 14 frontiersin.org FIGURE 5 The e ect of key mutations of SARS-CoV-2 variants on virus transmission and immune susceptibility.”
BackgroundInfluentialThe SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 33
Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
Ozer, E. A., Simons, L. M., Adewumi, O. M., Fowotade, A. A., Omoruyi, E. C., Adeniji, J. A., Dean, T. J., Zayas, J., Bhimalli, P. P., Ash, M. K., et al. (2021) · doi:10.1101/2021.04.09.21255206 · Cited by 34
Borisova, N. I., Kotov, I. A., Kolesnikov, A. A., Kaptelova, V. V., Speranskaya, A. S., Kondrasheva, L. Y., Tivanova, E. V., Khafizov, K., & Акимкин, В. Г. (2021) · Problems of Virology · doi:10.36233/0507-4088-72 · Cited by 33
Cassaniti, I., Bergami, F., Percivalle, E., Gabanti, E., Sammartino, J. C., Ferrari, A., Adzasehoun, K. M. G., Zavaglio, F., Zelini, P., Comolli, G., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.016 · Cited by 38
“7 (UK variant or a) includes multiple mutations in both the receptor binding domain (RBD) and the N-terminal domain of the S protein [12], and the 501Y.”
COVID-19: vaccines, efficacy and effects on variants
Rudan, I., Adeloye, D., & Sheikh, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000868 · Cited by 40
Temsah, M.-H. A., Barry, M. A., Aljamaan, F., Alhuzaimi, A., Al-Eyadhy, A. A., Saddik, B. A., Alsohime, F., Alhaboob, A. A. N., Alhasan, K. A., Alaraj, A., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.686958 · Cited by 36
Beigi, A., Yousefpour, A., Yasami, A., Gómez-Aguilar, J. F., Bekiros, S. D., & Jahanshahi, H. (2021) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-021-01620-8 · Cited by 32
“Moreover, this model could estimate the confirmed case very well from 23 to 29 January 2020 because it considered different parameter variations, and its data collection was performed during intensive social events [39].”
BackgroundMethodShim, E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147578 · Cited by 33
Genome Sequencing of SARS-CoV-2 Allows Monitoring of Variants of Concern through Wastewater
Herold, M., d’Hérouël, A. F., May, P., Delogu, F., Wienecke-Baldacchino, A. K., Tapp, J., Walczak, C., Wilmes, P., Cauchie, H., Fournier, G., et al. (2021) · Water · doi:10.3390/w13213018 · Cited by 36
Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in healthcare workers
Ferris, M., Ferris, R., Workman, C., O'Connor, E., Enoch, D., Goldesgeyme, E., Quinnell, N., Patel, P., Wright, J., Martell, G., et al. (2021) · eLife · doi:10.7554/elife.71131 · Cited by 38
Álvarez, L., Colom, M., Morel, J., & Morel, J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105112118 · Cited by 34
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 36
“The reproduction number in the Alpha lineage was higher by 43–90% than the preexisting variants, and the transmission increased in three countries, including Denmark, Switzerland, and the United States, fluctuating between 59 and 74% (29).”
BackgroundThe Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic
Torres, M. K. D. S., Bichara, C. D. A., de Almeida, M. D. N. D. S., Vallinoto, M. C., Queiroz, M. A. F., Vallinoto, I. M. V. C., dos Santos, E. J. M., de Carvalho, C. A. M., & Vallinoto, A. C. R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.789882 · Cited by 44
“Coronaviruses belong to the family Coronaviridae, which contains four genera (Alphacoronavirus, Betacoronavirus, Deltacoronavirus, and Gammacoronavirus) and includes species with a single-stranded RNA genome with positive polarity and 26–32 kb (International Committee on Taxonomy of Viruses [ICTV], 2019).”
Estimating SARS‐CoV‐2 infections and associated changes in COVID‐19 severity and fatality
Marziano, V., Guzzetta, G., Menegale, F., Sacco, C., Petrone, D., Mateo‐Urdiales, A., Manso, M. D., Bella, A., Fabiani, M., Vescio, M. F., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13181 · Cited by 35
Mbwogge, M. (2021) · JMIRx Med · doi:10.2196/27254 · Cited by 32
Chadha, J., Khullar, L., & Mittal, N. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15687 · Cited by 38
Wurtz, N., Revol, O., Jardot, P., Giraud‐Gatineau, A., Houhamdi, L., Soumagnac, C., Annessi, A., Lacoste, A., Colson, P., Aherfi, S., et al. (2021) · Pathogens · doi:10.3390/pathogens10081042 · Cited by 33
Stirrup, O., Boshier, F. A. T., Venturini, C., Guerra‐Assunção, J. A., Alcolea-Medina, A., Beckett, A. H., Charalampous, T., Filipe, A. D. S., Glaysher, S., Khan, T., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001029 · Cited by 34
The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in Mexico
Zárate, S., Taboada, B., Muñoz‐Medina, J. E., Iša, P., Sánchez‐Flores, A., Boukadida, C., Herrera‐Estrella, A., Mojica, N. S., Rosales-Rivera, M., Gómez‐Gil, B., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02240-21 · Cited by 31
Estimating the strength of selection for new SARS-CoV-2 variants
van Dorp, C. H., Goldberg, E. E., Hengartner, N., Ke, R., & Romero-Severson, E. O. (2021) · Nature Communications · doi:10.1038/s41467-021-27369-3 · Cited by 31
“Several studies using other methods have similarly found D614G and B.1.1.7 to each have a selective advantage over other variants circulating contemporaneously [14, 27, 3, 16, 2].”
InfluentialPARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2
Simon, V. R., Kota, V. K., Bloomquist, R. F., Hanley, H. B., Forgacs, D., Pahwa, S. G., Pallikkuth, S., Miller, L. G., Schaenman, J. M. D., Yeaman, M. R., et al. (2022) · mSphere · doi:10.1128/msphere.00179-22 · Cited by 29
Khairullin, B. M., Zakarya, K. D., Orynbayev, M. B., Abduraimov, Y. O., Kassenov, M. M., Sarsenbayeva, G., Sultankulova, K. T., Chervyakova, O. V., Myrzakhmetova, B. S., Куралбаевич, Н. А., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101526 · Cited by 38
(2022) · doi:10.1038/s41564-022-01092-1 · Cited by 98
Risk for International Importations of Variant SARS-CoV-2 Originating in the United Kingdom
Du, Z., Wang, L., Yang, B., Ali, S. T., Tsang, T. K., Shan, S., Wu, P., Lau, E. H. Y., Cowling, B. J., & Ancel, L. W. (2021) · Emerging infectious diseases · doi:10.3201/eid2705.210050 · Cited by 30
A Unique SARS-CoV-2 Spike Protein P681H Variant Detected in Israel
Zuckerman, N. S., Fleishon, S., Bucris, E. D., Bar-Ilan, D., Linial, M., Bar-Or, I., Indenbaum, V., Weil, M., Lustig, Y., Mendelson, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9060616 · Cited by 34
“The VOCs are fast spreading and characterized by higher infection rates or lower neutralization in convalescent or vaccinated individuals, consistent with evolutionary advantages for these variants [9,10].”
BackgroundAnti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants
Chaqroun, A., Hartard, C., & Schvoerer, É. (2021) · Viruses · doi:10.3390/v13061171 · Cited by 31
The variants question: What is the problem?
Zella, D., Giovanetti, M., Benedetti, F., Unali, F., Spoto, S., Guarino, M. P. L., Angeletti, S., & Ciccozzi, M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27196 · Cited by 30
Olsen, R. J., Christensen, P. A., Long, S. W., Subedi, S., Hodjat, P., Olson, R., Nguyen, M., Davis, J. J., Yerramilli, P., Saavedra, M. O., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.002 · Cited by 31
“7, last accessed June 9, 2021).(26) A similar rapid increase in B.”
Infectivity Upsurge by COVID-19 Viral Variants in Japan: Evidence from Deep Learning Modeling
Rashed, E. A., & Hirata, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18157799 · Cited by 31
“The estimated upsurge in Japan is around 20–40% in DPC and up to 20% in terms of effective reproduction number, which is relatively smaller than those reported in the UK [20].”
BackgroundResultInfluentialSalzer, R., Clark, J. J., Vaysburd, M., Chang, V. T.-C., Albecka, A., Kiss, L., Sharma, P., Llamazares, A. G., Kipar, A., Hiscox, J. A., et al. (2021) · FEBS Letters · doi:10.1002/1873-3468.14171 · Cited by 32
Detection of SARS-CoV-2 variant B.1.1.7 in a cat in Germany
Keller, M., Hagag, I. T., Balzer, J., Beyer, K., Kersebohm, J. C., Sadeghi, B., Wernike, K., Höper, D. W., Wylezich, C., Beer, M., et al. (2021) · Research in Veterinary Science · doi:10.1016/j.rvsc.2021.09.008 · Cited by 31
A small number of early introductions seeded widespread transmission of SARS-CoV-2 in Québec, Canada
Murall, C. L., Fournier, É., Gálvez, J. H., N’Guessan, A., Reiling, S. J., Quirion, P.-O., Naderi, S., Roy, A.-M., Chen, S., Stretenowich, P., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00986-9 · Cited by 32
Evaluation of the United States COVID-19 vaccine allocation strategy
Islam, M. R., Oraby, T. F., McCombs, A., Chowdhury, M. M., Al-Mamun, M. A., Tyshenko, M. G., & Kadelka, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259700 · Cited by 38
“351 with an estimated 50% increased transmissibility [21, 35], variants B.”
BackgroundO’Donnell, K. L., Pinski, A. N., Clancy, C. S., Gourdine, T., Shifflett, K., Fletcher, P., Messaoudi, I., & Marzi, A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103675 · Cited by 31
“Several studies have shown that the N501Y mutation harborded in both the B.1.1.7 and the B.1.351 variants utilized here increases ACE2 binding and enhances transmission capabilities [4,5,23].”
InfluentialRapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations
Ning, B., Youngquist, B. M., Li, D. D., Lyon, C. J., Zelazny, A. M., Maness, N. J., Tian, D., & Hu, Y. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100173 · Cited by 28
Chen, R., Zhang, X., Yuan, Y., Deng, X., Wu, B., Xi, Z., Wang, G., Lin, Y., Li, R., Wang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202105378 · Cited by 32
He, Q., Mao, Q., Peng, X., He, Z., Lu, S., Zhang, J., Gao, F., Bian, L., An, C., Yu, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00926-y · Cited by 32
Photonics enabled intelligence system to identify SARS-CoV 2 mutations
Taha, B. A., Al-Jubouri, Q., Mashhadany, Y. I. M. A., Zan, M. S. D., Bakar, A. A. A., Fadhel, M. M., & Arsad, N. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11930-1 · Cited by 34
Troyano-Hernáez, P., Reinosa, R., & Holguín, Á. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126394 · Cited by 37
Structural basis for Sarbecovirus ORF6 mediated blockage of nucleocytoplasmic transport
Gao, X., Tian, H., Zhu, K., Li, Q., Hao, W., Wang, L., Qin, B., Deng, H., & Cui, S. (2022) · Nature Communications · doi:10.1038/s41467-022-32489-5 · Cited by 35
Vecchio, C. D., Daniels, B. C., Brancaccio, G., Brazzale, A. R., Lavezzo, E., Ciavarella, C., Onelia, F., Franchin, E., Manuto, L., Bianca, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33460-0 · Cited by 32
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · medRxiv · doi:10.1101/2021.03.31.21254660 · Cited by 30
Althaus, C. L., Baggio, S., Reichmuth, M. L., Hodcroft, E. B., Riou, J., Neher, R. A., Jacquérioz, F., Spechbach, H., Salamun, J., Vetter, P., et al. (2021) · medRxiv · doi:10.1101/2021.06.10.21258468 · Cited by 38
Introduction and transmission of SARS-CoV-2 lineage B.1.1.7, Alpha variant, in Denmark
Michaelsen, T. Y., Bennedbæk, M., Christiansen, L. E., Jørgensen, M. S. F., Møller, C. H., Sørensen, E. A., Knutsson, S., Brandt, J., Jensen, T. B. N., Chiche-Lapierre, C., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01045-7 · Cited by 36
“Hypotheses for increased transmissibility include higher viral load, longer infection period, and better receptor binding [1, 12, 13].”
BackgroundSARS-CoV-2 variants and considerations of inferring causality on disease severity
Çevik, M., & Mishra, S. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00338-8 · Cited by 28
Metadata
- Authors
- Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M., Atkins, K. E., & Edmunds, W. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Selva Analytics LLC, Bozeman, MT, USA.
- KU Leuven (BE)
- Pennsylvania State University (US)
- Centre for Statistical Methodology and Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
- Corresponding author
- Davies, Nicholas G.
- ORCID
- Davies, Nicholas G.
- Abbott, Sam
- Barnard, Rosanna C.
- Jarvis, Christopher I.
- Kucharski, Adam J.
- Munday, James D.
- Pearson, Carl A. B.
- Russell, Timothy W.
- Tully, Damien C.
- Washburne, Alex D.
- Wenseleers, Tom
- Gimma, Amy
- Waites, William
- Wong, Kerry L. M.
- van Zandvoort, Kevin
- Silverman, Justin D.
- Diaz-Ordaz, Karla
- Keogh, Ruth
- Eggo, Rosalind M.
- Funk, Sebastian
- Jit, Mark
- Atkins, Katherine E.
- Edmunds, W. John
- Venue
- Science
- Published
- 2021-04-09
- Volume
- 372
- Issue
- 6538
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8128288
- OpenAlex
- W3134208712
- Semantic Scholar
- 34e9a0b4e42a4971a3a124c818045741c734fb9e
- Cited by
- 2,581
- References
- 58
- Citations by year
- 2026: 74 · 2025: 102 · 2024: 199 · 2023: 330 · 2022: 840 · 2021: 1028
- FWCI
- 215.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (submittedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion, cc-by)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Kentucky
- Universität Bern
- Universitätsspital Basel
- National Institute for Health Research (NIHR200908)
- European Commission (101003688)
- CANDU Owners Group
- Hôpitaux Universitaires de Genève
- Eidgenössische Technische Hochschule Zürich
- Université de Sfax
- UKRI Research England (NA)
- National Institute for Health Research Health Protection Research Unit in Immunisation (NIHR200929)
- United Kingdom Medical Research Council (MC_PC_19065)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- SARS-CoV-2, B.1.1.7 variant, reproduction number, SARS-CoV-2 transmission, epidemic forecasting, COVID-19 containment measures, vaccine rollout, school closures, England
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Communicable Disease Control, England, Europe, Female, Humans, Infant, Male, Middle Aged, Models, Theoretical, Mutation, Severity of Illness Index, Socioeconomic Factors, United States, Viral Load, Basic Reproduction Number, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.